Inmune Bio (INMB) Change in Account Payables (2018 - 2025)
Inmune Bio (INMB) posted Change in Account Payables of $81000.0 for Q2 2025, up 3.85% sequentially from $78000.0 in Q1 2025, and down 2.41% YoY from $83000.0 in Q2 2024.
Inmune Bio (INMB) Change in Account Payables (2018 - 2025) Analysis & Trends
Inmune Bio has reported Change in Account Payables for 8 years, with the latest figure at $81000.0 in Q2 2025.
- Quarterly Change in Account Payables fell 2.41% year-over-year to $81000.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $45000.0 (down 26.23% YoY) and the FY2024 annual result came in at -$10000.0, down 138.46% from the prior year.
- Change in Account Payables grew to $81000.0 in Q2 2025 per INMB's latest filing, from $78000.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $83000.0 in Q2 2024 and troughed at -$84000.0 in Q3 2024.
- A 5-year average of $5714.3 and a median of $0.0 in 2021 frame the typical range for Change in Account Payables.
- The sharpest annual moves came in 2023 and 2025: Change in Account Payables plunged 4500.0% in 2023, then jumped 271.43% in 2025.
- Over 5 years, Change in Account Payables stood at $70000.0 in 2021, then sank by 98.57% to $1000.0 in 2022, then slumped by 4500.0% to -$44000.0 in 2023, then soared by 31.82% to -$30000.0 in 2024, then jumped by 370.0% to $81000.0 in 2025.
- According to Business Quant data, Change in Account Payables over the past three periods registered $81000.0, $78000.0, and -$30000.0 for Q2 2025, Q1 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Inmune Bio | 61.59 Mn | 43.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 81,000.00 |
| Jun 30, 2025 | 81,000.00 |
| Mar 31, 2025 | 78,000.00 |
| Mar 31, 2025 | 78,000.00 |
| Dec 31, 2024 | -30,000.00 |
| Dec 31, 2024 | -30,000.00 |
| Sep 30, 2024 | -84,000.00 |
| Sep 30, 2024 | -84,000.00 |
| Jun 30, 2024 | 83,000.00 |
| Jun 30, 2024 | 83,000.00 |
| Mar 31, 2024 | 21,000.00 |
| Mar 31, 2024 | 21,000.00 |
| Dec 31, 2023 | -44,000.00 |
| Dec 31, 2023 | -44,000.00 |
| Dec 31, 2022 | 1,000.00 |
| Dec 31, 2022 | 1,000.00 |
| Sep 30, 2022 | -1,000.00 |
| Sep 30, 2022 | -1,000.00 |
| Mar 31, 2022 | -71,000.00 |
| Mar 31, 2022 | -71,000.00 |